Just few words, SPHS has a phase 2a valuable prostate cancer drug with good test data. The Market value is 35 Millions with more than 5 million cash. It does not take a genius to know this is way undervalued. My expectations in the next month or so we see partnership with a big pharma to take this to more than $4.00
We had a chance to speak with Darlene last week, and after listening to the recent 1Q earnings release conference call, we're somewhat convinced that both the asthma and anemia drugs are may follow the fate of PRS-050: discontinuation after proof-of-concept data
ECYT will be presenting this weekend. They have a new and improved product. CASH is market value plus research on top of it. Next week it will pass resistance to above 4.00, after that it is easy ride ..
Sentiment: Strong Buy